experienced 12 months lilly snatched small victory jaws defeat 2012 company reported difference patients taken solanezumab 18 months received placebo company reanalyzed trial found slight improvement participants symptoms mild trial began lilly continued test months began giving solanezumab 440 member control group disease advanced meeting lilly showed giving drug late start group slowed cognitive decline match rate seen 440 people treated entire study suggests drug targeted root alzheimer disease relieving symptoms biogen washington dc presented results moderate dose drug aducanumab reduced amyloid 23 people not statistically significant clinical benefits march company reported 27 people received high doses aducanumab year showed